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Summary.-Levamisole has been examined for its ability to control local growth
and pulmonary metastases of transplanted rat tumours. The compound did not
suppress subcutaneous growth of 3-methylcholanthrene induced sarcomata when
administered systemically in a variety of regimens, or when injected in admixture
with tumour cells. In addition, levamisole treatment failed to suppress pulmonary
growth of intravenously transferred sarcoma cells or spontaneous pulmonary
metastases appearing after surgical removal of a transplanted epithelioma.
LEVAMISOLE EXHIBITS a wide variety
of immunostimulatory properties,
adjuvanting humoral and cellular immu-
nity (Renoux and Renoux, 1971, 1972a;
Potter et at., 1974), restoring immuno-
logical reactivity in aged animals (Renoux
and Renoux, 1972b) and skin test hyper-
sensitivity in man, including cancer
patients, where cell mediated immunity is
impaired (Tripodi, Parks and Brugmans,
1973; Hirshaut et al., 1973; Verhaegen
et al., 1973). In addition, levamisole
treatment stimulates macrophage func-
tions in man and animals (Verhaegen et
al., 1973; Hoebeke and Franchi, 1973),
increasing phagocytosis without hyper-
plasia or hypertrophy of the reticulo-
endothelial system. These properties of
levamisole have encouraged its evaluation
as an immunotherapeutic agent in the
treatment of both experimental and
human tumours. Thus, Renoux and
Renoux (1972c) reported that levamisole
treatment of mice receiving subcutaneous
grafts of the Lewis lung carcinoma
prevented local tumour development and
reduced the incidence ofpulmonary metas-
tases. Clinically, Amery (1975) has
reported beneficial effects of levamisole
treatment in patients with resectable
bronchogenic carcinoma, while Webster
and Hughes (1975) are currently treating
patients with malignant melanoma and
carcinomata ofthe stomach and colon.
In contrast to the initial report by
Renoux and Renoux (1972c) with the
Lewis lung carcinoma, however, more
recent experimental studies with other
tumour types have failed to confirm the
tumour suppressive action of levamisole.
Thus, Potter et al. (1974) were unable to
suppress local growths or pulmonary
metastases with a range of 4 virus or
chemically induced mouse, rat and
hamster tumours by levamisole adminis-
tration, while treatment significantly
enhanced growth of an adenovirus 12-
induced tumour. With the rat Walker
256 tumour, repeated levamisole treat-
ment did not suppress tumour transplants
(Flannery, Rolland and Nairn, 1975) and
treatment was also without influence on
growth of a transplanted Moloney lym-
phoidleukaemia in mice (Chirigos, Pearson
and Pryor, 1973), although synergistic
effects were observed between the drug
andconventionalchemotherapeuticagents.
The objective of the present studies
was to extend theexperimental evaluation
of the tumour suppressive properties of
levamisole by examining its influence on
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transplanted 3-methylcholanthrene in-
duced rat sarcomata and also on the dev-
elopment of post-surgical pulmonary
metastases from a transplanted epithe-
1ioma. These tumours are currently being
used to design immunotherapeutic tech-
niques employingbacterial adjuvants, par-
ticularly Bacillus Calmette-Guerin (BCG),
and the results obtained by levamisole
treatment are compared with those pre-
viously reported with BCG.
MATERIALS AND METH-ODS
Tumours.-The tumours employed were
induced with chemical carcinogens or arose
spontaneously in rats of an inbred Wistar
strain and were maintained by subcutaneous
transplantation in syngeneic rats of the same
sex as the primary donor. Sarcomata Mc7
and Mc57, induced by subcutaneous implan-
tation of 3-methyleholanthrene, are highly
immunogenic so that animals immunized by
conventional techniques reject challenge with
up to 5 x 106 tumour cells. Epithelioma Spl
arose spontaneously (Baldwin, 1966) and is
weakly immunogenic so that immunized rats
can reject challenge with only 5 x 104 cells.
This tumour regularly produces pulmonary
metastases from subcutaneous growths, even
following their surgical removal (Baldwin
and Pimm, 1973a).
Single cell suspensions of tumour cells
were prepared by digestion of finely minced
tissue with 0.25% trypsin in Hanks' balanced
salt solution and washed and resuspended in
Medium 199.
Levamisole.-Levamisole (2,3,5,6-tetrahy-
dro-6-phenyl imidazo (2,16) thiazole) was
supplied by Janssen Pharmaceutica, Beerse,
Belgium. The compound was dissolved in
physiological saline and the solution sterilized
by passage through a 0-22 ,m Millipore filter.
Methods of treatment.-Rats (150-200 g
body weight) receiving subcutaneous or
intravenous challenge inocula ofsarcoma cells
were treated by single or repeated adminis-
tration of levamisole at 5 to 20 mg/kg body
weight given intraperitoneally, subcutan-
eously, intravenously by a lateral tail vein,
or orally by intra-oesophageal gastric instil-
lation. With epithelioma Spl, 9-14 day old
subcutaneous tumour growths were removed
surgically under ether anaesthesia, and rats
treated with 4-6 intravenous injections of
levamisole (5 mg/kg) starting one day after
surgery.
In some tests with sarcomata Mc7 and
Mc57, tumour cells were injected subcu-
taneously in admixture with levamisole
solution (1-5 mg levamisole/inoculum).
Assessment of tumour growth.-Subcu-
taneously developing tumours were measured
with calipers twice weekly and a mean
diameter calculated from measurements in
two planes. Animalsreceivingintravenously
injected sarcoma cells, or from which epithe-
lioma Spl grafts had been excised, were killed
individually when exhibiting respiratory
distress caused by growth of tumours in the
lungs. Statistical significance of the differ-
ence in survival between treated and control
rats was assessed by the Wilcoxon non-
parametric rank test. Pulmonary tumour
growths and spontaneous pulmonary metas-
tases were visualized by perfusion of lungs
with dilute India ink (Wexler, 1966) and the
number of macroscopically visible discrete
surface growths counted. Greater than 200
pulmonary deposits were scored as 200+.
RESUILTS
Treatment of subcutaneous tumotur growvths
In the first series of tests, subcu-
taneous growths of sarcomata Mc57 and
Mc7, initiated by injection of 1 X 106
tumour cells, were treated by repeated
administration of levamisole. These
experiments were designed to examine a
number of variables, including different
dose schedules (5-20 mg/kg body weight),
routes of administration and time of
initiation of treatment (Table I). In no
case, however, did these treatments either
prevent tumour appearance or retard
their progressive growth, in comparison
with untreated control rats. In 3 further
tests (Table II), the influence of localized
levamisole on subcutaneous tumour
development was assessed by injecting
tumour cells in direct admixture with the
agent, but again there was no inhibition
oftumour growth with either sarcoma.
Treatment ofpost-sargical metastases
Table III shows the influence of
levamisole treatment on the development
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TABLE I.-Influence ofLevamisole on Growth ofSubcutaneously Transplanted Rat
Sarcomata*
Sarcoma
Mc7
Mc57
Mc57
Mc57
Mc57
Dose
mg/kg
5
5
5
5
5
5
5
20
* 1 x 106 cells injected subcutaneously.
t With respect to tumour cell injection.
Levamisole treatment
te
Route Dayt
I.P.
S.C.
I.V.
I.P.
I.P.
I.P.
S.C.
I.V.
I.P.
TABLE II.-Growth of Rat Sarcomata
Injected Subcutaneously in Admixture
with Levamisole
Expt Sarcoma
1 Mc57
2 Mc57
3 Mc7
Mixed inoculum
A Tumour takes
mg in
No. of leva- ,-------)
cells misole Test Control
1 x 106 1-0 4/6 6/6
1 x 106 5 0 5/5 5/5
1 x 106 1.0 4/5 6/6
of pulmonary metastases appearing after
surgical excision of the transplanted
epithelioma Spl. In these tests small sub-
cutaneoustumourgrowths (meandiameter
1-2 cm) were removed surgically and rats
treated by 4-6 intravenous injections of
levamisole at 5 mg/kg/injection, starting
one day after tumour excision. In the
first test untreated animals all had to be
killed 28 days after initial tumour implan-
1, 4, 7, 10, 13, 16
1, 4, 7, 10, 13, 16
1, 4, 7, 10, 13, 16
0, 2, 4, 6, 8, 10, 12, 14, 16
0, 2, 4, 6, 8, 10, 12, 14, 16
1, 4, 7, 10, 13, 16
1, 4, 7, 10, 13, 16
1, 4, 7, 10, 13, 16
1, 4, 7, 10, 13
No. of
tumour takes
5/5
4/5
5/5
5/5
6/6
6/6
5/6
5/5
5/5
5/5
5/5
5/5
5/5
5/5
tation because of respiratory distress
caused by the development of pulmonary
metastases (3-170 nodules/lung). All
treated rats had to be killed at this time
and all of these also had pulmonary
metastases.
Treatment ofpulmonary tumour deposits
In view of the inability of levamisole
treatment to control the development of
spontaneous pulmonary metastases from
the weakly immunogenic epithelioma Spl,
further tests were carried out to assess
the influence of the compound on pul-
monary metastases produced by intra-
venous injection of cells of the highly
antigenic sarcoma Mc57 (Table IV).
Tumour cells (1 x 106 to 2 x 106) were
injectedintravenously and animalstreated
by single or repeated intravenous, sub-
TABLE III.-Levamisole Treatment of Pulmonary Metastases from Epithelioma Spl
following Surgical Removal ofSubcutaneous Tumours
Levamisole treatment
Dose A
mg/kg Route Day
5 I.V. 10, 13, 17, 20, 23, 25
5 I.V. 15, 18, 21, 24
* With respect to initial tumour implantation.
Survival
(days)
28
28
25
25
No. of rats
with
pulmonary
metastases
6/6
6/6
5/5
5/5
No. of
metastases/lung
3, 37, 82, 89, 150, 170
3, 7, 22, 80, 100, 200+
B x 200+
B x 200+
Expt
1
2
3
4
5
Expt
1
Tumour
excision
(day)*
9
2 14
347D. G. HOPPER, M. V. PIMM AND R. W. BALDWIN
0
(4.4 x
0 ~ ~ ++ 04 +++X
N ~ N XNN NN X
X-1 XI, X X X XI
~O'OC~0
~0 0 0o
X-4 c0Iqc o c
o4e~i E0
CO
X
a~~ 0XX_A
XtXt
--o-§leej w
--
0 < CO
G Oli
*C4
~ ~ ~ ~
_^~~0
_
0~~~
* -c -= $> C C
EV 0
'-d Ik0to co t to 0 Ikco 0 0
C4-4 ")0C>QC 0C 0 +
C)
4;>~~~~~~~*
348LEVAMISOLE TREATMENT OF TRANSPLANTED RAT TUMOURS
cutaneous or oral administration of leva-
misole (5 mg/kg). In the first test control
rats survived for 12-14 days, all having
in excess of 200 pulmonary deposits.
Subcutaneous and oral administration of
levamisole was without influence on the
survival of animals or on the numbers of
pulmonary tumour growths. Intraven-
ously injected levamisole prolonged sur-
vivals for up to 18 days but this was not
statisticallysignificant (P 0.1), although
1/5 rats was free of macroscopically
visible tumour deposits. All rats receiv-
ing levamisole intraperitoneally showed
significantly prolonged survival of up to
18 days (P < 0.005), and 2/5 animals
were found to have each developed only
one pulmonary tumour growth. This
effect was not reproduced in the second
test, however, where 9 intraperitoneal
injections of levamisole failed to prolong
survivals significantly, and all treated as
well as control rats had over 200 pul-
monary tumour growths. In the final
test, a single intravenous injection of
levamisole was also without discernible
influence on the pulmonary tumour growth
of this sarcoma.
DISCUSSION
The present studies demonstrate that
repeated systemic administration of leva-
misole at up to 20 mg/kg/injection by a
variety of routes exerts no suppressive
effect on growth of highly immunogenic
3-methylcholanthrene (Mc) induced sarco-
mata. Treatment also failed to affect
the post-surgical survival of rats from
which subcutaneous grafts of the weakly
immunogenic epithelioma Spl had been
excised. A small anti-tumour effect was,
however, obtained by repeated adminis-
tration of the drug at 5 mg/kg to animals
receiving intravenous challenge inocula
of the sarcoma Mc57, as reflected in a
prolongation of survival in one of two
tests.
The comparative ineffectiveness of
levamisole in the treatment ofrat tumours
described in this paper is in contrast
to the report by Renoux and Renoux
(1972c) where a single inijection of as
little as 0 5 mg/kg into mice receiving
grafts of the Lewis lung tumour com-
pletely prevented subcutaneous tumour
development in a proportion of animals
and significantly reduced the development
of pulmonary metastases. However, in
other similar studies Potter et al. (1974)
founid that repeated levamisole injections
at the same dose (0.5 ing/kg) failed to
influence the growth of a transplanted
CELO-virus induced hamster tumour, a
Moloney virus induced mouse lymphoma,
or the incidence ofprimary and metastatic
growth of a chemically induced trans-
planted rat tumour. Furthermore, treat-
ment significantly enhanced growth of a
transplanted adenovirus 12 induced
hamster tumour (Potter et al., 1974)
and was without influence on growth of
Walker 256 tumour in rats (Flannery et
al., 1975).
In addition to its general immuno-
stimulatory properties, levamisole stimu-
lates macrophage functions in man and
animals (Verhaegen et al., 1973; Hoebeke
and Franchi, 1973), activating phago-
cytosis without hyperplasia or hyper-
trophy of the reticuloendothelial system.
It is well established (reviewed by Laucius
et al., 1974) that Bacillus Calmette-
Guerin (BCG) organisms when injected
in direct admixture with tumour cells
may suppress their growth. This effect
is most probably mediated by local
activation of macrophages since it can be
abrogated by silica-induced host macro-
phage depletion (Pimm and Hopper,
1975). In the present studies, therefore,
tests were carried out to examine the
tumour suppressive action of levamisole
when it, too, was injected directly in
admixture with tumour cells, but again
the compound did not suppress the growth
of either of two Mc induced sarcomata.
This finding contrasts markedly with
previousstudiesemployinglocallyadminis-
tered BCG. Here, pronounced suppres-
sive effects were achieved by the intro-
duction of viable or radiation killed BCG
directly into the site of tumour growth,
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either subcutaneously in admixture with
tumour cells (Baldwin and Pimm, 1971,
1973b; Baldwin et al., 1974), or into
pulmonary tissue by intravenous injec-
tion to control growth of pulmonary
tumour growths, including post-surgical
metastases from the epithelioma Spl
(Baldwin and Pimm, 1973a, c).
A further property of levamisole is
its ability to restore immunological reacti-
vity in aged animals and anergic patients
(Renoux and Renoux, 1972b; Tripodi et
al., 1973; Hirshaut et al., 1973; Verhaegen
et at., 1973). In this context, Chirigos
et al (1973) reported that while levamisole
alone had no effect on growth ofa Moloney
virus induced murine leukaemia, marked
protective effects were achieved when
the drug was administered during BCNU
induced tumour remission. This syner-
gistic effect between conventional chemo-
therapy and levamisole treatment has
been interpreted as due to early restora-
tion ofcell mediated immunity, destroying
remaining tumour cells when at a minimal
level (Perk et al., 1975). Similar tests
are in progress to assess the combined
effects oflevamisole and chemotherapeutic
agents in the treatment ofthe rat tumours
described in this paper. However, the
conclusion from the present studies is that
levamisole, while reported to have a broad
spectrum of immunological effects, may
not necessarily be as effective as other
adjuvants if used alone as an immuno-
therapeutic agent, and further experi-
mental studies may be needed to form a
rational basis for a clinical application of
the compound.
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